BioLink Drug Outperforms Competitors

Share Article

In preclinical tests, BioLink's new iron compound, BioFeRx, consistently outperforms current treatments for people with iron deficiencies.

BioLink Life Sciences, Inc. announced today that new preclinical data obtained at Cornell University have confirmed that BioLink's new iron compound, BioFeRx™, consistently outperforms current treatments for people with iron deficiencies. "Most people take iron tablets containing ferrous sulfate," BioLink's President Deanna Nelson noted. "Ferrous sulfate causes nausea, black stools, and other more serious side effects. In contrast, BioFeRx™ has no taste and exhibited far fewer side effects in our test system. Its performance consistently topped that of the current iron treatments, including ferrous sulfate, Ferrochel®, and Ferrazone®."

Iron supplements are used by pregnant women, people with kidney disease, and people recovering from chemotherapy. BioLink is working to complete metabolic and clinical trials that will validate the way in which BioFeRx™ restores and maintains iron in the body. If the preclinical results are confirmed, as expected, people taking BioFeRx™ will enjoy significant energy boosts, endurance and vigor.

BioLink Life Sciences, Inc. is a pharmaceutical development company that "repairs" drugs to reduce side effects and improve their safety, a strategy that significantly reduces the time and cost of development for FDA approval. The Company works with pharmaceutical partners to commercialize, market, and distribute its drug candidates.

To learn more about BioLink's products, contact BioLink at (919) 678-9478, or visit the company's website at

Ferrochel® is a product of Albion Laboratories. Ferrazone® is a product of Akzo Nobel.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Deanna Nelson
Visit website